Grants and Contributions:

Title:
Providence COVID-19 Vaccine Development - STAGE 3
Agreement Number:
998413
Agreement Value:
$10,000,000.00
Agreement Date:
Sep 1, 2022 - Mar 15, 2023
Description:
Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.
Organization:
National Research Council Canada
Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:
Calgary, Alberta, CA T2Z 3P2
Reference Number:
172-2022-2023-Q3-998413
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
738045079
Recipient Type:
For-profit organization
Recipient's Legal Name:
Providence Therapeutics Holdings Inc.
Federal Riding Name:
Calgary Shepard
Federal Riding Number:
48011
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
3254